SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...

HYDERABAD: India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

A global elderly and aging population has significant impacts, not only in terms of individual health risk but in terms of ...

The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...

ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...

Q4 2024 Earnings Call Transcript February 26, 2025 Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.08. Operator: Ladies and gentlemen, good ...

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...

Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Phase 2 open-label study of paltusotine in carcinoid syndrome reported positive results. In March 2024, Crinetics reported ...